Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.
Neurology. 2019.
PMID: 31515290
Free PMC article.